COMP <GO>
SMMT vs UNH // ALTMAN Z-SCORE & DEBT/EQUITY
Summit Therapeutics Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: SMMT 3
— UNH 9
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: SMMT
LAST: $15.80 (+6.76%) • MKT CAP: $11.84B
balance-sheet
26.00
LAST: $404.44 (+1.00%) • MKT CAP: $359.43B
balance-sheet
3.09
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SMMT VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SMMT | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.31% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 12.38% | -47.38 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.50% | 6.25% | -8.75 | UNH | /fcf-yield <GO> |
| Operating Margin | -36.30% | 5.32% | -41.62 | UNH | /operating-margins <GO> |
| Net Profit Margin | -29.80% | 3.53% | -33.33 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 11.00% | 3.33% | +7.67 | SMMT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 26.00 | 3.09 | +22.91 | SMMT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.4 | 55.1 | -13.70 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.97 | 0.33 | +0.64 | SMMT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.0x | 17.7x | +16.26 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.84B | $359.43B | -$347.60B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SMMT REV | UNH REV | SMMT GROSS % | UNH GROSS % | SMMT FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.57B | $447.57B | — | 88.7% | -$323.6M | $16.07B |
| FY 2024 | $632.8M | $400.28B | — | 88.3% | -$142.2M | $20.70B |
| FY 2023 | $1.71B | $371.62B | — | 89.6% | -$76.8M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SMMT // BETA 0.97
UNH // BETA 0.33